(IOVA) Iovance Biotherapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.540m USD | Total Return: 134.9% in 12m

Cell Therapies, Immunotherapy, Interleukin-2, Cancer Biologics
Total Rating 38
Safety 32
Buy Signal 0.08
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.54B
Avg Turnover: 39.7M
Risk 3d forecast
Volatility91.4%
VaR 5th Pctl13.4%
VaR vs Median-13.2%
Reward TTM
Sharpe Ratio1.18
Rel. Str. IBD91.8
Rel. Str. Peer Group78.3
Character TTM
Beta1.949
Beta Downside2.215
Hurst Exponent0.531
Drawdowns 3y
Max DD90.50%
CAGR/Max DD-0.24
CAGR/Mean DD-0.39
EPS (Earnings per Share) EPS (Earnings per Share) of IOVA over the last years for every Quarter: "2021-03": -0.51, "2021-06": -0.53, "2021-09": -0.55, "2021-12": -0.63, "2022-03": -0.58, "2022-06": -0.63, "2022-09": -0.63, "2022-12": -0.64, "2023-03": -0.5, "2023-06": -0.47, "2023-09": -0.46, "2023-12": -0.45, "2024-03": -0.42, "2024-06": -0.34, "2024-09": -0.28, "2024-12": -0.26, "2025-03": -0.36, "2025-06": -0.33, "2025-09": -0.25, "2025-12": -0.18, "2026-03": -0.19,
Last SUE: -1.21
Qual. Beats: -1
Revenue Revenue of IOVA over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0.238, 2023-09: 0.469, 2023-12: 0.482, 2024-03: 0.715, 2024-06: 31.106, 2024-09: 58.554, 2024-12: 73.694, 2025-03: 49.324, 2025-06: 59.952, 2025-09: 67.455, 2025-12: 86.771, 2026-03: 71.43,
Rev. CAGR: 1520.38%
Rev. Trend: 92.0%
Last SUE: -0.33
Qual. Beats: 0

Warnings

Share dilution 29.6% YoY

Altman Z'' -15.00 < 1.0 - financial distress zone

Overextended 3d Choppy

Tailwinds

Leader, Tailwind

Description: IOVA Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a San Carlos-based biopharmaceutical firm specializing in the development and commercialization of autologous tumor-infiltrating lymphocyte (TIL) therapies. Its primary commercial offerings include Amtagvi, an individualized T-cell therapy for advanced melanoma, and Proleukin, used for metastatic renal cell carcinoma and melanoma. The company’s pipeline extends to multiple solid tumor indications, including cervical, lung, and endometrial cancers, supported by strategic collaborations with the National Cancer Institute and various global pharmaceutical entities.

The biotechnology sector often requires significant capital expenditure and long-term research cycles, as cell therapies involve complex manufacturing processes to customize treatments for individual patients. Iovance operates under a high-specialization business model where autologous therapies utilize a patients own immune cells, distinguishing its clinical approach from traditional off-the-shelf pharmaceuticals. Investors may find it useful to examine ValueRay for deeper insights into the company’s competitive positioning. Originally incorporated as Lion Biotechnologies, the firm transitioned to its current name in 2017 to reflect its focus on innovative immuno-oncology solutions.

Headlines to Watch Out For
  • Amtagvi commercial launch and patient uptake drive immediate revenue growth
  • Expansion of TIL therapy into non-small cell lung cancer markets
  • Manufacturing scale and centralized facility utilization impact gross margins
  • Regulatory approval timelines for lifileucel in international jurisdictions
  • High research and development spend necessitates future capital raises
Piotroski VR-10 (Strict) 0.5
Net Income: -353.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.33 > 0.02 and ΔFCF/TA 2.99 > 1.0
NWC/Revenue: 118.0% < 20% (prev 183.4%; Δ -65.33% < -1%)
CFO/TA -0.29 > 3% & CFO -270.8m > Net Income -353.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.60 > 1.5 & < 3
Outstanding Shares: last quarter (418.5m) vs 12m ago 29.62% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 30.18% > 50% (prev 22.00%; Δ 8.19% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.36 (Total Current Assets 466.5m - Total Current Liabilities 129.4m) / Total Assets 925.7m
B: -3.08 (Retained Earnings -2.85b / Total Assets 925.7m)
C: -0.38 (EBIT TTM -360.2m / Avg Total Assets 946.2m)
D: -13.94 (Book Value of Equity -2.84b / Total Liabilities 203.9m)
Altman-Z'' = -24.86 = D
Beneish M -3.68
DSRI: 0.86 (Receivables 81.8m/70.9m, Revenue 285.6m/212.7m)
GMI: 0.22 (GM 97.45% / 21.72%)
AQI: 1.01 (AQ_t 0.31 / AQ_t-1 0.30)
SGI: 1.34 (Revenue 285.6m / 212.7m)
TATA: -0.09 (NI -353.9m - CFO -270.8m) / TA 925.7m)
Beneish M = -3.68 (Cap -4..+1) = AAA
What is the price of IOVA shares?

As of May 24, 2026, the stock is trading at USD 3.70 with a total of 10,576,995 shares traded.
Over the past week, the price has changed by +19.13%, over one month by +16.43%, over three months by +42.21% and over the past year by +134.86%.

Is IOVA a buy, sell or hold?

Iovance Biotherapeutics has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy IOVA.

  • StrongBuy: 5
  • Buy: 3
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the IOVA price?
Analysts Target Price 8.8 137.8%
Iovance Biotherapeutics (IOVA) - Fundamental Data Overview as of 24 May 2026
P/S = 5.3935
P/B = 2.2364
Revenue TTM = 285.6m USD
EBIT TTM = -360.2m USD
EBITDA TTM = -326.8m USD
Long Term Debt = 43.9m USD (estimated: total debt 46.8m - short term 2.90m)
Short Term Debt = 2.90m USD (from shortTermDebt, last quarter)
Debt = 46.8m USD (from shortLongTermDebtTotal, last quarter) (leases 48.4m already included)
Net Debt = -266.7m USD (calculated: Debt 46.8m - CCE 313.4m)
Enterprise Value = 1.27b USD (1.54b + Debt 46.8m - CCE 313.4m)
 Interest Coverage Ratio = unknown (Ebit TTM -360.2m / Interest Expense TTM 0.0)
 EV/FCF = -4.18x (Enterprise Value 1.27b / FCF TTM -305.0m)
FCF Yield = -23.95% (FCF TTM -305.0m / Enterprise Value 1.27b)
 FCF Margin = -106.8% (FCF TTM -305.0m / Revenue TTM 285.6m)
 Net Margin = -123.9% (Net Income TTM -353.9m / Revenue TTM 285.6m)
 Gross Margin = unknown ((Revenue TTM 285.6m - Cost of Revenue TTM 7.29m) / Revenue TTM)
 Tobins Q-Ratio = 1.38 (Enterprise Value 1.27b / Total Assets 925.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 46.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -284.6m (EBIT -360.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.60 (Total Current Assets 466.5m / Total Current Liabilities 129.4m)
Debt / Equity = 0.06 (Debt 46.8m / totalStockholderEquity, last quarter 721.8m)
 Debt / EBITDA = 0.82 (negative EBITDA) (Net Debt -266.7m / EBITDA -326.8m)
 Debt / FCF = 0.87 (negative FCF - burning cash) (Net Debt -266.7m / FCF TTM -305.0m)
 Total Stockholder Equity = 705.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.40% (Net Income -353.9m / Total Assets 925.7m)
RoE = -9.94% (Net Income TTM -353.9m / Total Stockholder Equity 3.56b)
RoCE = -10.00% (EBIT -360.2m / Capital Employed (Equity 3.56b + L.T.Debt 43.9m))
 RoIC = -39.62% (negative operating profit) (NOPAT -284.6m / Invested Capital 718.2m)
 WACC = 12.46% (E(1.54b)/V(1.59b) * Re(12.84%) + D(46.8m)/V(1.59b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 24.43%
 [DCF] Fair Price = unknown (Cash Flow -305.0m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.21 | # QB: -1
Revenue Correlation: 91.97 | Revenue CAGR: 1.52k% | SUE: -0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.14 | Chg30d=-10.80% | Revisions=-14% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.14 | Chg30d=-14.45% | Revisions=-14% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.58 | Chg30d=-15.33% | Revisions=-20% | GrowthEPS=+46.9% | GrowthRev=+37.1%
EPS next Year (2027-12-31): EPS=-0.33 | Chg30d=-38.59% | Revisions=-20% | GrowthEPS=+42.3% | GrowthRev=+44.7%
[Analyst] Revisions Ratio: -20%